Scribe Therapeutics Reports Q2 2026 Results: STX-1150 Enters Clinic, Cash Runway to 2029
SCTX sits 79% above its 52-week low of $17.305.
Summary
Scribe Therapeutics reported Q2 2026 results with a narrower net loss, initiated the Phase 1 trial of lead asset STX-1150, and confirmed cash runway into 2029 following its July IPO.
Key Events · Earnings and Guidance · SCTX
-
Q2 Net Loss Narrows to $6.5M
Net loss was $6.5 million ($2.62/share) for Q2 2026, down from $9.9 million ($4.08/share) in Q2 2025, driven by lower R&D and G&A expenses.
-
Cash Runway Extended to 2029
Cash of $43.0 million as of June 30, 2026, plus approximately $140.6 million in net IPO proceeds, funds operations into the first half of 2029.
-
STX-1150 Phase 1 Trial Initiated
First-in-human Phase 1 trial of STX-1150, an epigenetic silencing therapy for LDL-C lowering, began in Australia in mid-2026; initial clinical data expected in the first half of 2027.
-
$25.7M in CIRM Grants Awarded
Non-dilutive grants of $12.7M for STX-1200 (Lp(a) lowering) and $13.0M for STX-1400 (triglyceride lowering) to advance both toward clinical entry as early as 2027.
Analysis · SCTX · Life Sciences
Scribe Therapeutics disclosed its first quarterly results as a public company, revealing a narrower net loss of $6.5 million versus $9.9 million a year earlier, alongside a cash position of $43.0 million that, combined with $140.6 million in net IPO proceeds, funds operations into the first half of 2029. The company also initiated the first-in-human Phase 1 trial of its lead asset STX-1150 in Australia and secured $25.7 million in non-dilutive CIRM grants for two additional cardiometabolic programs. These developments mark the company's transition from preclinical to clinical-stage and provide investors with the first concrete financial and operational baseline since the July IPO.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1753 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCTX was trading at $30.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $582.9M. The 52-week trading range was $17.31 to $39.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.